Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration (Q38032311)

From Wikidata

Jump to navigation Jump to search

scientific article published on 07 August 2012

Language	Label	Description	Also known as
English	Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration	scientific article published on 07 August 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

thromboembolism

1 reference

based on heuristic

inferred from title

Ciro Costagliola

object named as

Ciro Costagliola

1

0 references

author name string

Luca Agnifili

2

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Barbara Arcidiacono

3

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Sarah Duse

4

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Vincenzo Fasanella

5

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Rodolfo Mastropasqua

6

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Marco Verolino

7

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Francesco Semeraro

8

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

language of work or name

0 references

publication date

7 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Expert Opinion on Biological Therapy

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

1299-1313

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

The epidemiology of age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Gender and estrogen supplementation increases severity of experimental choroidal neovascularization

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with amd after bevacizumab treatment.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Vascular endothelial growth factor: basic science and clinical progress

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Vascular endothelial growth factor is a secreted angiogenic mitogen

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Pathogenesis of persistent hyperplastic primary vitreous in mice lacking the arf tumor suppressor gene

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

VEGF and KDR gene expression during human embryonic and fetal eye development

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

HIF hydroxylation and the mammalian oxygen-sensing pathway

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Vascular endothelial growth factor biology: clinical implications for ocular treatments

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Role of endothelium in thrombosis and hemostasis

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

The role of endothelial cell apoptosis in inflammatory and immune diseases

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Angiogenic growth factors and hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Managing patients treated with bevacizumab combination therapy.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Dicephalic parapagus conjoined twins: a rare second trimester sonographic diagnosis

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Retinal artery occlusion following intravitreal anti-VEGF therapy.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

VEGF inhibition and renal thrombotic microangiopathy

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

The biology of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Age-dependent impairment of reendothelialization after arterial injury: role of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Vascular Endothelial Growth Factor Regulates Reendothelialization and Neointima Formation in a Mouse Model of Arterial Injury

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Bevacizumab: off-label use in ophthalmology

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Aptamers, intramers, and vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

VEGF164Is Proinflammatory in the Diabetic Retina

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Ranibizumab for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Inhibitors of ocular neovascularization: promises and potential problems.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

VEGF-Trap: a VEGF blocker with potent antitumor effects

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Aflibercept (VEGF-TRAP): the next anti-VEGF drug

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Pharmacokinetics of intravitreal ranibizumab (Lucentis).

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Clearance of intravitreal moxifloxacin

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Pharmacokinetics and safety of intravitreally delivered etanercept

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Early breakdown of the blood-retinal barrier in diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Cellular mechanisms of blood-retinal barrier dysfunction in macular edema

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Pegaptanib for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Should avastin be used to treat age-related macular degeneration in the NHS?--No

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Risks of Mortality, Myocardial Infarction, Bleeding, and Stroke Associated With Therapies for Age-Related Macular Degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Anti-VEGF Compounds in the Treatment of Neovascular Age Related Macular Degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

The expanding role of vascular endothelial growth factor inhibitors in ophthalmology

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

New roles for VEGF in nervous tissue--beyond blood vessels

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707176

21 January 2018

Identifiers

10.1517/14712598.2012.707176

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38032311&oldid=2043623321"